Articles tagged with Prostate Cancer
Researchers found that older men with high-risk prostate cancer who received hormone therapy lived longer and experienced fewer PSA increases compared to those without treatment. A longer duration of hormone therapy resulted in improved overall survival rates, especially among those over 70.
A large cohort study found that hormone therapy before radiation seed implants for prostate cancer increases the risk of death by 20% in men over 70 years old with early-stage cancer. This treatment approach may have negative effects on survival, particularly for older patients.
A new web site, CaP Calculator, provides cancer specialists with access to the latest research and helps them individualize patient treatment options. The tool allows doctors to evaluate the risk of disease spreading and the effectiveness of surgery and radiation treatment.
The American Urological Association has released a best practice statement on cryosurgery, recommending it as an option for men with clinically organ-confined prostate cancer. The panel of experts emphasized the importance of case selection and recommended maximizing results through temperature monitoring and double freeze cycles.
A randomized study found that adding radiation therapy to hormone treatment reduces the risk of dying from prostate cancer by 50% compared to hormone therapy alone. The quality of life at four years after treatment was similar between the two groups, with decreased social function in patients who received combined treatment.
Researchers found that genetic programs forming the prostate in embryos are similar to those driving tumor growth in prostate cancers. They identified genes involved in cell survival, growth, and movement that are activated in both normal development and aggressive prostate cancers.
Common painkillers such as aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker used to gauge prostate cancer risk. However, the study does not prove a direct link between the medications and reduced risk of prostate cancer.
Regular NSAID use can reduce serum PSA levels, potentially altering prostate cancer detection in individuals taking these medications. Chronic inflammation linked to prostate cancer may be masked by NSAIDs, which inhibit COX enzymes.
Researchers at Wake Forest University School of Medicine have found a second independent site within the HNF1B gene that may contribute to the risk of developing prostate cancer. The new discovery strengthens the link between genetic variants and prostate cancer risk, improving the ability to predict prostate cancer risk.
A study from Columbia University's Mailman School of Public Health found associations between smoking, obesity, and physical inactivity with lower Prostate Specific Antigen (PSA) awareness. This may lead to reduced prostate cancer screening rates among affected individuals.
Researchers have found that a common treatment for advanced prostate cancer can actually cause some cancer cells to grow, rather than stopping them. The androgen receptor plays a versatile role in the disease, acting as both a tumor promoter and suppressor in different cell types.
A randomized trial found that radical prostatectomy reduces prostate cancer death rates, with benefits lasting beyond 10 years. However, the applicability of these results to modern prostate cancer patients is unclear due to the widespread use of PSA screening.
A study published by researchers at Duke University Medical Center found that only one-fifth of men under age 50 reported undergoing a PSA test in the previous year. Black men and men with a family history are disproportionately affected, highlighting the need for increased awareness and screening efforts.
A study found that one in five men in their 40s have undergone a PSA test within the previous year. Young black men are more likely than young white men to have been screened. The study also revealed that younger Hispanic men and those with higher household income and education level were more likely to undergo testing.
Research finds that PSA screening can lead to delayed diagnosis and more aggressive cancer outcomes for obese men. The study suggests that alternative screening methods or lower threshold for worrisome PSA levels may be necessary for this population.
Research shows Vietnam War veterans exposed to Agent Orange have increased risks of prostate cancer and aggressive forms of the disease compared to those not exposed. The study, conducted on over 13,000 men in their 60s, found twice as many exposed veterans developed prostate cancer.
The USPSTF recommends against routine prostate cancer screening for men over 75 due to insufficient evidence. In contrast, the task force found that chronic illness is common among uninsured Americans, affecting an estimated 11.4 million adults with conditions like cardiovascular disease and hypertension.
The USPSTF recommends against routine prostate cancer screening for men over 75 due to insufficient scientific evidence showing improved health outcomes. Men under 75 may benefit from screening with more evidence needed, according to the updated recommendations.
A new study reveals significant variations in prostate cancer care quality by region, hospital type, and race, suggesting areas for improvement to enhance patient outcomes. Compliance rates with standardized measures vary greatly among healthcare facilities, highlighting the need for standardization.
A recent review of the literature found that hormone deprivation therapy can have subtle adverse effects on cognition in prostate cancer patients. Studies indicate that between 47% and 69% of men treated with androgen depletion therapy decline in at least one cognitive area, primarily in spatial ability and high-order capacities.
A recent review of literature found that hormone deprivation therapy can have subtle adverse effects on cognition in prostate cancer patients, affecting recall, concentration, and high-order capacities. Between 47% and 69% of men treated with androgen depletion therapy decline in cognitive function.
A comprehensive study of 31 countries found significant variations in cancer survival rates, with the US and Europe experiencing lower survival rates compared to other regions. The study reveals a racial gap in cancer survival between black and white populations in the US, with blacks facing a 7-14% lower survival rate.
Using an engineered virus, UCLA researchers locate prostate cancer cells in the pelvic lymph nodes, where it spreads first before invading other organs. The discovery may lead to more effective diagnostic and therapeutic approaches for advanced prostate cancer.
A mouse study reveals that sex-specific growth hormone secretion patterns mediate gender-associated differences in susceptibility to diseases caused by inappropriate thrombosis. Additionally, research identifies the protein FGF9 as a key player in prostate cancer progression to osteoblastic bone metastases.
For elderly men with localized prostate cancer, androgen deprivation therapy does not improve survival rates compared to conservative management. The study found lower 10-year prostate cancer-specific survival rates among those using PADT.
Researchers found that circulating tumor cell counts accurately predict treatment response and survival in castration-resistant prostate cancer. Patients with declining cell counts showed improved prognosis, reflecting potential therapy benefits.
Researchers have discovered two drugs that can improve memory in a mouse model of Alzheimer's disease by inhibiting calpains. Additionally, they found stabilizing molecules for the faulty PAH protein in phenylketonuria (PKU), and identified a genetic marker for predicting prostate cancer spreading.
A study published in PLOS ONE found that eating broccoli rich in glucosinolates can help men stay healthy and reduce the risk of developing prostate cancer. The research, led by Professor Richard Mithen, showed that relatively low amounts of cruciferous vegetables can have large effects on gene expression.
Researchers at CCNY have demonstrated the efficacy of Cytate as a fluorescence marker to detect prostate cancer. The contrast agent exhibited greater fluorescence when applied to cancerous tissue, with a peak ratio of 3.57 between cancerous and normal tissues.
Researchers at UT Southwestern Medical Center have identified a panel of seven biomarkers that can predict prostate cancer recurrence with 86 percent accuracy. This finding holds promise for personalized medicine and targeted therapy, potentially improving treatment outcomes and patient care.
A study found that radiation treatment after radical prostatectomy was associated with a significant increase in prostate cancer-specific and overall survival. Men with rapid PSA doubling time or high Gleason score benefited from early salvage radiotherapy, which improved survival by over 75%.
A study of 635 men found that radiation therapy significantly prolongs survival in those with recurrent prostate cancer, particularly those with rapidly growing tumors. This breakthrough suggests that radiation can be a life-extending treatment option for these patients.
Researchers identified SPINK1 as a biomarker for an aggressive type of prostate cancer that accounts for 10% of cases. The discovery could lead to a simple urine test to diagnose this variation, which tends to recur quickly.
Researchers at OHSU Cancer Institute found that Ipilimumab effectively stimulates the immune system to fight prostate cancer, particularly in patients with resistant tumors. The drug works by blocking CTLA-4, releasing the safety brake and allowing the immune response to have a stronger anti-tumor effect.
Researchers found that metastatic prostate tumors produce significant levels of testosterone, fueling cancer growth despite low circulating androgen levels. This discovery suggests targeting the tumor itself, rather than systemic hormone suppression, to develop more effective treatments for all stages of prostate cancer.
Researchers at Jefferson University have identified a key signaling protein that enables prostate cancer cells to metastasize. Blocking this protein, Stat3, can prevent prostate cancer from spreading, offering new potential therapies.
Researchers at OHSU Cancer Institute found that Sagopilone, a novel chemo drug, significantly reduced PSA levels and showed positive results in some cases of advanced prostate cancer. The study involved men with androgen-independent prostate cancer that has metastasized.
Researchers found that FruHis, a carbohydrate in dehydrated tomato products, has strong protective effects against prostate cancer. The study shows that a diet rich in tomato paste and FruHis led to the longest survival rate among rats with prostate cancer.
A recent study suggests that dehydrated tomato products containing the organic carbohydrate FruHis may have strong anti-cancer properties. In an animal study, rats fed with a diet rich in FruHis and tomato paste showed longer survival from cancer compared to those without these ingredients.
Researchers analyzed vitamin D concentrations in 749 men with prostate cancer and 781 without, finding no correlation between vitamin D levels and prostate cancer risk. However, higher vitamin D levels were associated with increased risks of aggressive disease, but the association was not statistically significant.
Researchers have found estrogen-dependent molecular pathways play a crucial role in regulating aggressive prostate cancer. The study used innovative technology to analyze 455 prostate cancer samples and identified an 87-gene expression signature that distinguishes fusion-positive TMPRSS2-ERG cancers from other malignancies.
A recent analysis found that most US health news stories have major failings in reporting, including inadequate discussion of costs, harms, and benefits. The study graded 500 US health news stories, resulting in a high rate of poor reporting, highlighting the need for improved standards in health journalism.
Researchers at Thomas Jefferson University have developed a new ultrasound technique that targets areas of increased blood flow in the prostate gland, significantly reducing the number of unnecessary biopsies. The study found that targeted biopsies were twice as likely to detect cancer compared to conventional methods.
An experimental drug, OSU-HDAC42, has blocked prostate cancer progression in mice with an aggressive form of the disease. The agent reactivates genes that normally protect against cancer, shifting tumor progression to a more benign direction.
A re-analysis of PCPT data reveals that finasteride significantly reduces the incidence of prostate cancers, including higher-grade ones. The study also suggests that finasteride may suppress indolent cancers and could be useful in determining tumor aggressiveness.
Researchers have identified a specific gene expression profile of prostate cancer stem cells, revealing key pathways and potential therapeutic targets. The study's findings offer new hope for treatments targeting the rare but aggressive cancer stem cells.
A new study shows that DCE-MRI plus DWI can accurately diagnose residual or recurrent prostate cancer, improving patient outcomes. The two imaging studies have a combined accuracy rate of about 72% in detecting cancer after HIFU ablation.
New data suggests finasteride may be more effective than previously thought in preventing prostate cancer. The study analyzed over 18,000 men and found a significant reduction in aggressive tumors and an increased prevention of clinically significant disease.
Researchers found a 27% reduced incidence of prostate cancer in mice on a low-fat diet compared to those on a Western-style diet. The study suggests that lowering dietary fat intake may slow the growth of precancerous cells and prevent prostate cancer development.
Researchers found that a single PSA reading taken at age 44-50 can predict prostate cancer diagnosis up to 30 years subsequently, even in men below age 40. The study suggests possible prolonged periods of prostate cancer pre-malignancy and the relationship between PSA and advanced cancer development.
A study found that external-beam radiation therapy for localized prostate cancer increases the rate of secondary malignancies, including a 3.0-fold increase in bladder cancer, compared to radical prostatectomy. This predisposition is observed in lung-cancer resections and rectal cancer as well.
Only a small proportion of diagnosed low-risk prostate cancers will progress to life-threatening disease during a patient's lifetime. Recorded incidence has increased due to screening and improved diagnosis, but mortality rates have not kept pace, suggesting that most low-risk cases may remain stable or even decrease over time.
Researchers found that African-American men with a family history of prostate cancer are unlikely to develop the disease if their baseline PSA level is below the age-specific median. In contrast, those with high baseline PSA levels are more likely to develop prostate cancer, even with other risk factors.
Two studies presented at AUA 2008 found that active surveillance is a viable option for low-risk prostate cancer patients. The studies highlighted the importance of reliable clinical predictors of disease progression and showed that endorectal MRI was the most reliable predictor of disease progression.
A new therapeutic vaccine has shown promising results in prolonging survival and improving the quality of life for men with metastatic prostate cancer. The adenovirus/PSA vaccine demonstrated strong immune responses to PSA, leading to improved patient outcomes.
A new study reveals that prostate cancer screening programs and access to urologists are significantly linked to reduced mortality rates. The research, presented at the AUA 2008 conference, found that higher urologist population densities and PSA screening rates correlate with lower mortality rates.
A study published in Clinical Cancer Research found that genetic polymorphisms are associated with a lower risk of prostate cancer among Hispanic men. The research suggests that these genetic variations may help clinicians predict who is more likely to develop the disease, potentially reducing unnecessary screenings and treatments.
Men aged 75-80 with PSA levels below 3 ng/ml are unlikely to develop aggressive disease and may safely discontinue screening. The study's findings could lead to a reduction in unnecessary treatment for non-aggressive prostate cancers.
A new study strengthens the association between exposure to Agent Orange and an increased risk of developing prostate cancer in aging Vietnam veterans. The study found that twice as many exposed men were diagnosed with prostate cancer, diagnosed at a younger age, and more likely to present with aggressive disease.
A new study suggests that therapies inhibiting IGF-1 signaling in prostate cancer may not work as expected in tumors with a compromised p53 gene. The research, conducted by investigators at Fred Hutchinson Cancer Center, found that eliminating IGF-1R expression led to hyperplastic cell growth and proliferation in mouse prostates.